Intel CEO Pat Gelsinger has resigned after less than four years, as the board deemed his ambitious turnaround plan ineffective. His departure comes amidst a significant drop in Intel’s stock value, and the appointment of interim co-CEOs David Zinsner and Michelle Johnston Holthaus. Gelsinger’s strategy aimed to restore Intel’s chip-making dominance, but faced challenges, particularly in AI chip competition.
Read Full StoryHezbollah launched projectiles into a disputed border area with Israel, marking its first attack since a recent ceasefire began. The militant group claims the strike was a response to Israeli violations of the truce, which Lebanon alleges have occurred over 50 times. Despite the ceasefire brokered by the U.S. and France, tensions remain high, with ongoing Israeli strikes in Lebanon.
Read Full StoryGoogle faces significant threats as competition rises from AI-driven search engines, shifting user preferences to platforms like Amazon and TikTok, and a decline in search result quality due to AI-generated content. These trends, coupled with the Justice Department’s antitrust actions, could jeopardize Google’s dominance and revenue, leading to long-term declines in its core business.
Read Full StorySam Altman’s relationship with Elon Musk has soured amid Musk’s new alignment with Donald Trump, following a lawsuit Musk filed against Altman, alleging betrayal of OpenAI’s nonprofit mission. Musk’s growing influence raises concerns for rivals like Altman, as he positions himself closely with the incoming administration. The feud intensifies, complicating the AI sector’s regulatory landscape.
Read Full StoryDuring his visit to Hawaii, Taiwan President Lai Ching-te expressed hopes for continued U.S. support under the incoming Trump administration, similar to that received from Biden. Lai held meetings with American politicians, addressed criticisms from Trump, and emphasized Taiwan’s commitment to self-defense and cooperation in the semiconductor industry amidst rising tensions with China.
Read Full StoryInvestors are flocking to two high-risk exchange-traded funds (ETFs) linked to MicroStrategy’s volatile stock and its significant bitcoin holdings. These ETFs aim to double daily returns but have faced performance issues, disappointing investors. As their reliance on complex derivatives increases, analysts warn of unsustainable market euphoria and potential losses, raising concerns over their risk exposure.
Read Full StoryApple’s Lockdown Mode, introduced in 2022, offers enhanced security for users at risk, such as activists and journalists, by disabling certain features that hackers exploit. While effective, this mode limits device functionality, raising questions about its necessity for average users. Experts suggest individuals assess personal risk versus convenience before enabling the feature. Android lacks a similar security option.
Read Full StoryBYD, China’s leading electric-vehicle maker, assembles over 30% of Apple’s iPads. With a workforce of 100,000 dedicated to Apple’s supply chain, BYD exemplifies Apple’s reliance on Chinese manufacturing despite efforts to diversify. The partnership highlights the blending of automotive and tech industries in China, with BYD also supplying components for rivals like Samsung and Xiaomi.
Read Full StoryIn her autobiography, Najma Heptulla recounts her experience after being elected president of the Inter-Parliamentary Union in 1999, highlighting a frustrating call with Sonia Gandhi. Disappointed by Gandhi’s lack of communication, Heptulla reflects on the decline of Congress under Gandhi’s leadership, contrasting it with previous open-door policies of Indira Gandhi. She emphasizes the growing disconnect within the party.
Read Full StoryAmgen’s obesity drug candidate, MariTide, shows promise by helping patients lose about 20% of their body weight, yet it faces significant competition from established leaders Eli Lilly and Novo Nordisk. While MariTide’s unique mechanism offers potential advantages, side effects remain a concern. Analysts suggest that despite the competition, MariTide could still capture a notable market share in the lucrative obesity drug market.
Read Full Story